Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891

Pembrolizumab-induced agranulocytosis.

Fernández Martínez V, García-Avello Fernández-Cueto A, Valencia Soto CM, Barbadillo Villanueva S, Ochagavía Sufrategui M, Rioja Carrera M, Alonso Buznego LA, Valero Domínguez M
J Oncol Pharm Pract 2024 Jun;30(4):767-771. Epub 2024 Jan 30 doi: 10.1177/10781552241228774. PMID: 38291678

Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?

Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR
Clin Lung Cancer 2023 Jul;24(5):401-406. Epub 2023 Apr 25 doi: 10.1016/j.cllc.2023.03.014. PMID: 37208221

Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.

Si JF, Xiang J, Wei JW, Hao Y, Song ZB
Neoplasma 2022 Jul;69(4):976-982. Epub 2022 May 23 doi: 10.4149/neo_2022_220329N348. PMID: 35603955

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175 Free PMC Article

See all (51)

Diagnosis

Pembrolizumab-induced agranulocytosis.

Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy: a case report.

Shrestha P, George MK, Baidya S, Rai SK
J Med Case Rep 2022 May 5;16(1):184. doi: 10.1186/s13256-022-03323-9. PMID: 35513831 Free PMC Article

Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics.

Li F, Ye P, Cai P, Dong D, Zhang Y, Yang Y, Sun X
PLoS One 2022;17(1):e0262822. Epub 2022 Jan 21 doi: 10.1371/journal.pone.0262822. PMID: 35061839 Free PMC Article

High incidence of EGFR mutations in pneumonic-type non-small cell lung cancer.

Liu J, Shen J, Yang C, He P, Guan Y, Liang W, He J
Medicine (Baltimore) 2015 Feb;94(8):e540. doi: 10.1097/MD.0000000000000540. PMID: 25715252 Free PMC Article

Emphasizing on heat shock protein 90's utility in head and neck squamous cell carcinoma treatment.

Routray S, Sunkavalli A, Swain N, Shankar AA
J Cancer Res Ther 2013 Oct-Dec;9(4):583-6. doi: 10.4103/0973-1482.126451. PMID: 24518700

See all (27)

Therapy

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.

Pembrolizumab-induced agranulocytosis.

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A
Cancer Res 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. PMID: 37311042

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Camrelizumab: First Global Approval.

Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098

See all (96)

Prognosis

Pembrolizumab-induced agranulocytosis.

Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?

Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR
Clin Lung Cancer 2023 Jul;24(5):401-406. Epub 2023 Apr 25 doi: 10.1016/j.cllc.2023.03.014. PMID: 37208221

Analysis of bevacizumab treatments and metastatic sites of lung cancer.

Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Immunotherapy for Advanced Lung Cancer.

Asmar R, Rizvi NA
Cancer J 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. PMID: 26389763

See all (51)